Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with…
Andrea Lobo, —
Articles by Andrea Lobo
Cero seeking more safety, dosing data on T-cell therapy for AML
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in…
New drug for endometrial cancer wins FDA’s breakthrough status
The U.S. Food and Drug Administration (FDA) has awarded breakthrough therapy status to rinatabart sesutecan (Rina-S), an investigational treatment for certain cancers, including advanced endometrial…
Daraxonrasib granted breakthrough designation for pancreatic cancer
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
1st patient dosed in trial of PRMT5 inhibitor for glioblastoma
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
Provider genetic testing may raise gynecological cancer testing rates
Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…
Trial to test relacorilant combo in platinum-resistant ovarian cancer
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with…
Study of NKT3964 in gynecological, other cancers advances
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
Phase 1b/2 trial of CLD-101 for aggressive glioma now recruiting
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the effects of multiple doses of…
